10.6084/m9.figshare.c.3627356_D2.v1 Kim Papp Kim Papp Robert Bissonnette Robert Bissonnette Melinda Gooderham Melinda Gooderham Steven Feldman Steven Feldman Lars Iversen Lars Iversen Jennifer Soung Jennifer Soung Zoe Draelos Zoe Draelos Carla Mamolo Carla Mamolo Vivek Purohit Vivek Purohit Cunshan Wang Cunshan Wang William Ports William Ports Additional file 1: of Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial Springer Nature 2016 Psoriasis Topical Tofacitinib CP-690,550 Physician’s Global Assessment Psoriasis Area and Severity Index PASI Dermatology Life Quality Index Pruritus Itch 2016-10-03 05:00:00 Journal contribution https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Treatment_of_plaque_psoriasis_with_an_ointment_formulation_of_the_Janus_kinase_inhibitor_tofacitinib_a_Phase_2b_randomized_clinical_trial/4412861 Figure S1. Change from baseline in DLQI through Week 16. Table S1. Serious adverse events by treatment group. Table S2. Number and percent of plasma tofacitinib concentration samples (pre-dose and post-dose) by concentration range – available data mild/moderate - post hoc. Table S3. Summary of plasma tofacitinib pharmacokinetic parameters - available data at week 4 - mild/moderate - post hoc. (DOCX 238 kb)